Myelofibrosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

(Albany, USA) DelveInsight's "Myelofibrosis Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myelofibrosis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Myelofibrosis market report covers emerging drugs, treatment practices, market share of individual Myelofibrosis therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current Myelofibrosis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

As per DelveInsight, the Myelofibrosis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Myelofibrosis and the launch of new therapies in the market.

Myelofibrosis Market Report Key Facts
• The Myelofibrosis market in the seven major markets is expected to increase during the study period (2020-2034) with a CAGR of 7.3%.
• In 2024, the market size of myelofibrosis was highest in the US among the 7MM, accounting for approximately USD ~1,700 million, which is further expected to increase by 2034.
• In the 7MM, among all the therapies JAKAFI/JAKAVI (ruxolitinib) accounted for the largest market size in 2024, with approximately USD ~1,500 million.
• JAK inhibitors have emerged as the centerpiece of pharmacologic therapy for patients with myelofibrosis, providing unprecedented benefits in terms of spleen shrinkage, symptom improvement, and quality of life that can enhance longevity in patients with advanced disease.
• According to the estimates, the highest market size of Myelofibrosis is found in the United States, followed by Japan.
• In 2024, the total number of prevalent myelofibrosis cases across the 7MM was approximately 55,900, with this number expected to grow throughout the forecast period (2020-2034).
• Within the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent myelofibrosis cases, followed by Spain, while the UK had the fewest cases in 2024.
• When categorized by risk level-low, intermediate-1, intermediate-2, and high-the high-risk group represented the largest patient population in the United States in 2024.
• In January 2025:- Sumitomo Pharma America Inc.:- This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
• In January 2025:- Keros Therapeutics Inc.:- KER-050 is an investigational therapeutic protein designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias including anemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF)
• In January 2025:- Geron Corporation:- The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
• In January 2025:- Karyopharm Therapeutics Inc.:- This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b).
• In January 2025:- Ryvu Therapeutics SA:- The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.
• The leading Myelofibrosis Companies such as Incyte Corporation, Keros Therapeutics, Karyopharm Therapeutics, Celgene Corporation, PharmaEssentia, Novartis, SecuraBio, Pharmaxis, Novartis Oncology, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohmoncology, Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Celgene/Bristol-Myers Squibb, MorphoSys, Imago BioSciences, and Roche.
• Myelofibrosis pipeline includes drugs such as BESREMi (PharmaEssentia and AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb and Merck), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), RVU120 (Ryvu Therapeutics), TP-3654 (Sumitomo Pharma), SNT-5505 (Syntara), DISC-0974 (Disc Medicine), and ELZONRIS (Menarini Group), among others

Discover How the Myelofibrosis Market Will Grow by 2034 @ https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Overview
Myelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibers. Myelofibrosis can be of two types: primary myelofibrosis and secondary myelofibrosis.
Primary myelofibrosis (also called Chronic Idiopathic Myelofibrosis, agnogenic myeloid metaplasia) develops on its own, due to certain genetic mutations. It occurs most often between ages 50 and 70 years, mostly in men. Secondary myelofibrosis occurs as a result of other disorders, particularly other blood disorders such as chronic myeloid leukemia, polycythemia vera, thrombocythemia, multiple myeloma, and lymphoma.
Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.

Myelofibrosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Myelofibrosis therapies in the market. It also provides a detailed assessment of the Myelofibrosis market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete details of the market trend for each marketed Myelofibrosis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Myelofibrosis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2020 to 2034.
The Report Covers the Myelofibrosis Epidemiology Segmented as -
• Total Prevalent Cases of Myelofibrosis in the 7MM (2020-2034)
• Total Diagnosed Prevalent cases of Myelofibrosis in the 7MM (2020-2034)
• Type-specific Prevalent Cases of Myelofibrosis in the 7MM (2020-2034)
• Transplant Eligible/Ineligible Cases of Myelofibrosis in the 7MM (2020-2034)
• Myelofibrosis Cases Based on Molecular Alterations in the 7MM (2020-2034)
• Age-specific Prevalent Cases of Myelofibrosis in the 7MM (2020-2034)
• Myelofibrosis cases Based on Risk Stratification in the 7MM (2020-2034)

Get Key Insights Into the Evolving Myelofibrosis Epidemiology Trends @ https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelofibrosis market or expected to be launched during the study period. The analysis covers the market share by Myelofibrosis drugs, patient uptake by therapies, and sales of each drug.
The Myelofibrosis market report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The Myelofibrosis market report also covers the Myelofibrosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Myelofibrosis Market @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Therapeutics Assessment
The treatment goal for most patients with myelofibrosis is to relieve symptoms, reduce an enlarged spleen, improve blood cell counts (i.e., anemia), and reduce the risk of complications. No drug therapy can cure myelofibrosis. The only potential cure for myelofibrosis is allogeneic stem cell transplantation, but this procedure is risky for older patients and those with other health problems. As myelofibrosis primarily affects older adults, stem cell transplantation is not a treatment option for most myelofibrosis patients. For most people with myelofibrosis, treatment remains aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival.
Several major pharma and biotech companies are actively engaged in the development of therapies for Myelofibrosis, a serious bone marrow disorder. Among these companies, Incyte Corporation takes a prominent position, with its Myelofibrosis drug candidates progressing to the most advanced stage of clinical development, specifically in Phase III trials.

Leading Companies in the Myelofibrosis Therapeutics Market Include
Notable players in the Myelofibrosis Therapeutics Market Include Incyte Corporation, Keros Therapeutics, Karyopharm Therapeutics, Celgene Corporation, PharmaEssentia, Novartis, SecuraBio, Pharmaxis, Novartis Oncology, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohmoncology, Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Celgene/Bristol-Myers Squibb, MorphoSys, Imago BioSciences, and Roche.

Emerging and Marketed Myelofibrosis Therapies Covered in the Report Include
• Parsaclisib: Incyte Corporation
• KER-050: Keros Therapeutics
• Momelotinib: Sierra Oncology
• Navitoclax (ABT-263): AbbVie
• Parsaclisib (INCB050465): Incyte
• REBLOZYL (Luspatercept/ACE-536): Celgene/Bristol Myers Squibb
• Pelabresib: MorphoSys
And Many Others

Learn More About the Emerging Therapies and key Companies in the Myelofibrosis Therapeutics Market @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Myelofibrosis Competitive Intelligence Analysis
4. Myelofibrosis Market Overview at a Glance
5. Myelofibrosis Background and Overview
6. Myelofibrosis Patient Journey
7. Myelofibrosis Epidemiology and Patient Population
8. Myelofibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Myelofibrosis Unmet Needs
10. Key Endpoints of Myelofibrosis Treatment
11. Myelofibrosis Marketed Products
12. Myelofibrosis Emerging Therapies
13. Myelofibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Myelofibrosis Market Outlook (7 major markets)
16. Myelofibrosis Access and Reimbursement Overview
17. KOL Views on the Myelofibrosis Market.
18. Myelofibrosis Market Drivers
19. Myelofibrosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.